Skip to content

The clinical efficacy of Jinghua Weikang as an alternative to bismuth agents in the treatment of gastric ulcers with Helicobacter pylori (Hp) infection and its impact on inflammatory factors.

Correlation Between Helicobacter pylori and Metabolic Dysfunction-Associated Steatohepatitis (MASLD) and Diagnostic Value of Cytokeratin 18 for MASLD

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000076
Enrollment
Unknown
Registered
2026-01-17
Start date
2024-03-16
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric ulcer

Interventions

Control Group:Colloidal bismuth citrate + amoxicillin + doxycycline + vonoprazan fumarate tablets
Research Group:Jinghua Weikang capsules + Amoxicillin + Doxycycline + Vonoprazan fumarate tablets

Sponsors

Hainan Medical University First Affiliated Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Meets the diagnostic criteria for gastric ulcer, confirmed by gastroscopy; 2) Tested positive for Helicobacter pylori infection by 13C-urea breath test within one week prior to enrollment; 3) Aged between 18 and 65 years old; 4) Has not previously received Helicobacter pylori eradication therapy; 5) The patient and their family have given informed consent and signed the informed consent form; 6) Able to cooperate and complete the entire treatment process and follow-up.

Exclusion criteria

Exclusion criteria: 1) Patients allergic to the medications used in this study (Jinghua Weikang, colloidal bismuth citrate, amoxicillin, doxycycline, vonoprazan); 2) Patients with concomitant gastric malignant lesions (such as gastric cancer); 3) Patients with malignant tumors in other locations; 4) Patients with severe diseases of vital organs such as the heart, liver, kidneys, or brain, who cannot tolerate treatment; 5) Pregnant or breastfeeding women; 6) Patients with impaired consciousness, mental illness, etc., who cannot cooperate with the study; 7) Patients who have used other medications affecting Helicobacter pylori detection or gastric ulcer treatment within the past week; 8) Patients with incomplete data that prevents effective statistical analysis.

Design outcomes

Primary

MeasureTime frame
Clinical Efficacy Overall Effective Rate;

Secondary

MeasureTime frame
Ulcer area;Helicobacter pylori eradication rate;Helicobacter pylori recurrence rate;inflammatory factor;toxic adverse reaction;

Countries

China

Contacts

Public ContactXu Qi

Hainan Medical University First Affiliated Hospital

95309018@qq.com18889690742

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026